These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 2857148

  • 1. Recent developments in the treatment of Parkinson's disease.
    Greer M.
    Geriatrics; 1985 Feb; 40(2):34-8, 41. PubMed ID: 2857148
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The drug treatment of Parkinson's disease.
    Morris JG.
    Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767
    [Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy: problems and practices.
    Muenter MD.
    Clin Neuropharmacol; 1986 May; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Update on drug treatment of Parkinsonism.
    Winkelman AC.
    Am Fam Physician; 1977 Jul; 16(1):118-20. PubMed ID: 18001
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I, Gawel MJ, Riopelle RJ, Bouchard S.
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M, Miwa H, Kondo T.
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [Abstract] [Full Text] [Related]

  • 15. Pharmacology of Parkinson's disease.
    Burton K, Calne DB.
    Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
    [Abstract] [Full Text] [Related]

  • 16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 17. Update on the treatment of Parkinson's disease.
    Wirz D.
    Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Parkinson's disease: new treatments.
    Stewart RM.
    Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986
    [Abstract] [Full Text] [Related]

  • 20. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.